Apricot Therapeutics AG (APx), a spin-off from the University of Zürich, is positioning itself to become the Google maps of the cell by applying image-based systems biology approaches that were developed over 10 years at the University of Zürichs Pelkmans Lab. The problem were solving is the inability to accurately predict how molecular structure-based compounds (e.g. drugs) impact the human cell while outside the human body. Closing this gap will mean a treating physician will have the ability (with high accuracy) to predict which drug will heal a patient. When the 4i technology platform is successfully adopted by e.g. i) Hospitals and/or ii) big Pharma, Apricot will help to achieve the holy grail in healthcare by creating a new targeted medicine industry